Stay updated on Adagrasib with Nab-Sirolimus in KRAS G12C NSCLC Clinical Trial
Sign up to get notified when there's something new on the Adagrasib with Nab-Sirolimus in KRAS G12C NSCLC Clinical Trial page.

Latest updates to the Adagrasib with Nab-Sirolimus in KRAS G12C NSCLC Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedMinor formatting updates and small text edits are present, with no changes to core study details (title, NCT number, eligibility criteria, outcomes, or current status). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check32 days agoChange DetectedAdded a government operating status notice and a v3.2.0 revision; removed the previous v3.1.0 revision. The page now communicates potential service delays and open NIH Clinical Center status, plus the updated software version.SummaryDifference4%

- Check40 days agoChange DetectedVersion update: from v3.0.2 to v3.1.0. The change is limited to the revision label; no other page content or data appears to be altered.SummaryDifference0.1%

- Check54 days agoChange DetectedThe page now declares Revision: v3.0.2, replacing the previous v3.0.1, indicating a maintenance release. The 'Back to Top' link was removed, a minor UI change.SummaryDifference0.3%

- Check61 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.3%

- Check68 days agoChange DetectedThe web page has undergone significant updates, including the addition of new facility names and locations related to cancer treatment, while removing several specific terms and references to previous content, particularly in the area of cancer types and drug classifications.SummaryDifference3%

Stay in the know with updates to Adagrasib with Nab-Sirolimus in KRAS G12C NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Adagrasib with Nab-Sirolimus in KRAS G12C NSCLC Clinical Trial page.